BMRA BIOMERICA INC
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 73290 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.2%
TTM net income YoY-37.0%
TTM EPS YoY-9.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin0.9%
Operating margin-125.2%
Net margin-115.5%
FCF margin—
EBITDA margin-123.6%
Returns
ROE-113.8%
ROA-67.1%
ROIC (approx.)-284.4%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets54.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 | FY20242024-05-31 | FY20232023-05-31 | FY20222022-05-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.45M | $5.31M | $5.42M | $5.34M | $18.87M |
| Cost of revenue | $4.09M | $4.81M | $4.80M | $4.89M | $15.89M |
| Gross profit | $362,000 | $498,000 | $611,000 | $446,000 | $2.98M |
| R&D expense | $788,000 | $1.02M | $1.49M | $1.58M | $1.81M |
| SG&A expense | $4.89M | $4.61M | $5.49M | $6.08M | $5.70M |
| Operating income | -$5.32M | -$5.14M | -$6.37M | -$7.22M | -$4.53M |
| Pretax income | -$3.75M | -$4.97M | -$5.94M | -$7.09M | -$4.51M |
| Income tax | $23,000 | $1,000 | $42,000 | $51,000 | $24,000 |
| Net income | -$3.77M | -$4.97M | -$5.98M | -$7.14M | -$4.53M |
| EBITDA | -$5.24M | -$5.05M | -$6.29M | -$7.14M | -$4.20M |
| EPS (basic) | -1.30 | -2.16 | -2.84 | -0.50 | -0.36 |
| EPS (diluted) | -1.30 | -2.16 | -2.84 | -0.50 | -0.36 |
| Weighted avg. shares (diluted) | 2.91M | 2.30M | 2.10M | 14.15M | 12.67M |
| Balance sheet | |||||
| Cash & equivalents | $1.31M | $2.40M | $4.17M | $9.72M | $5.92M |
| Receivables | $785,000 | $731,000 | $947,000 | $722,000 | $774,000 |
| Inventory | $1.71M | $1.49M | $2.38M | $2.06M | $2.42M |
| Current assets | $4.02M | $4.88M | $7.73M | $12.80M | $9.43M |
| PP&E, net | $78,000 | $135,000 | $201,000 | $213,000 | $214,000 |
| Intangibles | $209,000 | $228,000 | $212,000 | $165,000 | $170,000 |
| Total assets | $6.76M | $5.95M | $9.25M | $14.45M | $11.37M |
| Current liabilities | $2.48M | $1.74M | $2.20M | $1.95M | $2.01M |
| Total liabilities | $4.13M | $1.84M | $2.66M | $2.73M | $3.05M |
| Shareholders' equity | $2.63M | $4.11M | $6.59M | $11.72M | $8.32M |
| Shares outstanding | 3.20M | 2.55M | 2.10M | 16.82M | 12.87M |
| Cash flow statement | |||||
| Operating cash flow | -$3.42M | -$3.84M | -$5.36M | -$5.47M | -$479,000 |
| Capital expenditure | — | — | $51,000 | $64,000 | $57,000 |
| Free cash flow | — | — | -$5.41M | -$5.54M | -$536,000 |
| Investing cash flow | -$1,000 | -$37,000 | -$115,000 | -$78,000 | -$170,000 |
| Financing cash flow | $2.33M | $2.11M | -$81,000 | $9.39M | $2.39M |
| Depreciation & amortization | $77,000 | $87,000 | $81,000 | $84,000 | $339,000 |
| Stock-based compensation | $476,000 | $460,000 | $837,000 | $1.19M | $1.26M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.